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Abstract: Insulin resistance and islet (beta and alpha) cell dysfunction are major pathophysiologic 
abnormalities in type 2 diabetes mellitus (T2DM). Pioglitazone is a potent insulin sensitizer, 
improves pancreatic beta cell function and has been shown in several outcome trials to lower the 
risk of atherosclerotic and cardiovascular events. Glucagon-like peptide-1 deficiency/resistance 
contributes to islet cell dysfunction by impairing insulin secretion and increasing glucagon secretion. 
Dipeptidyl peptidase-4 (DPP-4) inhibitors improve pancreatic islet function by augmenting 
glucose-dependent insulin secretion and decreasing elevated plasma glucagon levels. Alogliptin 
is a new DPP-4 inhibitor that reduces glycosylated hemoglobin (HbA1c), is weight neutral, has an 
  excellent safety profile, and can be used in combination with oral agents and insulin. Alogliptin has 
a low risk of hypoglycemia, and serious adverse events are uncommon. An alogliptin–pioglitazone 
combination is advantageous because it addresses both insulin resistance and islet dysfunction in 
T2DM. HbA1c reductions are significantly greater than with either monotherapy. This once-daily 
oral combination medication does not increase the risk of hypoglycemia, and tolerability and 
discontinuation rates do not differ significantly from either monotherapy. Importantly, measures 
of beta cell function and health are improved beyond that observed with either monotherapy, 
potentially improving durability of HbA1c reduction. The alogliptin–pioglitazone combination 
represents a pathophysiologically sound treatment of T2DM.
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Introduction
The prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic   proportions and 
continues to rise.1 Currently, T2DM has been diagnosed in nearly 24 million Americans 
and is projected to affect nearly 50 million individuals by 2050. Increases in T2DM are 
paralleled by a robust increase in people at high risk for the development of diabetes. 
Prediabetes, as of 2007, may be present in up to 57 million individuals through the 
diagnosis of impaired fasting glucose (100–125 mg/dL) or impaired   glucose tolerance 
(IGT, two-hour value on a 75 g oral glucose tolerance test [OGTT] of 140–199 mg/dL).1 
It is imperative to understand that development of diabetes is not inevitable with 
prediabetes. Lifestyle interventions and medications, which will be discussed, may be 
appropriate in select patients to prevent progression to diabetes. In T2DM,   hyperglycemia 
is the key determinant of microvascular complications,2 and the evidence that improving 
glycemic control lowers the risk of microvascular complications is unequivocal. 
Hyperglycemia also contributes to macrovascular complications,3 although to a lesser 
extent. As demonstrated in the United Kingdom Prospective Diabetes Study, glycemic 
control deteriorates   progressively over time in T2DM patients treated with sulfonlyureas, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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metformin, and/or insulin.2,4 In ADOPT (A Diabetes Outcome 
Progression Trial), the thiazolidinedione (TZD) rosiglitazone 
markedly slowed the rise in glycosylated hemoglobin (HbA1c) 
in newly   diagnosed T2DM patients versus sulfonylureas 
or metformin, but even monotherapy with the TZD could 
not completely arrest the deterioration of glycemic control 
over the five years of follow-up.5 Although the progressive 
  worsening of glycemic control can be controlled with lifestyle 
intervention combined with aggressive stepwise addition of 
multiple hypoglycemic agents,3,4 clinicians often intervene 
with additional antihyperglycemic agents only when the HbA1c 
has risen to values that are well above target.6 To overcome 
this problem of clinical inertia and to achieve optimal HbA1c 
goals, early combination therapy with agents that minimize 
the risk of hypoglycemia and address the multiple underlying 
pathophysiologic abnormalities has been advocated to assist 
clinicians in attaining and maintaining glycemic goals.7
In the US, most clinicians initiate therapy with metformin, 
especially if the patient is overweight. Because metformin 
improves glucose control, reduces cardiovascular   complications 
in obese patients with T2DM, and is generic, this biguanide 
represents a logical choice as first-line therapy in diabetic 
patients.4 Addition of a TZD or a sulfonylurea is commonly 
employed as the next step by most clinicians. Sulfonylureas 
are generic and inexpensive, but are inferior to metformin and 
TZDs with respect to durability of HbA1c reduction,5 may cause 
hypoglycemia, and impart no other nonglycemic advantages 
to the T2DM patient. Most importantly, sulfonylureas, like 
metformin, do not preserve beta cell function.
The core pathophysiologic disturbances (insulin   resistance 
and impaired insulin secretion) that are   present in T2DM can 
be ameliorated by improving muscle/hepatic   insulin   sensitivity 
with the addition of a TZD and   correction of glucagon-like 
peptide-1 (GLP-1) deficiency. GLP-1   agonists (exenatide 
and liraglutide) and dipeptidyl   peptidase-4 (DPP-4)   inhibitors 
(  sitagliptin, saxagliptin, vildagliptin, and alogliptin) improve 
insulin secretion by   pancreatic beta cells, and decrease the 
  elevated rate of glucagon secretion by alpha cells. GLP-1 
r  eceptors have been identified in the pancreas (beta and alpha 
cells), kidney, heart, stomach, lung, and brain.8,9 GLP-1 enhances 
glucose-dependent insulin secretion, causes glucose-dependent 
suppression of elevated glucagon secretion, slows gastric emp-
tying, and reduces food intake. Because the effects of GLP-1 
on insulin and glucagon secretion wane as the fasting glucose 
level returns to normal, hypoglycemia is minimized in T2DM 
patients treated with GLP-1-based therapy. The glucoregulatory 
mechanisms by which GLP-1 and exenatide/liraglutide act are 
similar, but GLP-1 suppresses gastric acid secretion, whereas 
exenatide and liraglutide do not.10 DPP-4 inhibitors augment 
insulin secretion and inhibit glucagon release, but do not slow 
gastric emptying and are weight neutral.11
Given that approximately 50% of T2DM patients have 
HbA1c levels greater than 7% despite currently available 
therapies to control glycemia,12–14 adverse metabolic effects 
are often cited as therapeutically limiting by clinicians, and 
clinical inertia remains a major problem, combination therapy 
can help to overcome these multiple barriers. In practice, the 
combination of an insulin sensitizer (metformin or a TZD) 
with a GLP-1 analog or a DPP-4 inhibitor minimizes the risk 
of hypoglycemia and weight gain, and can help to achieve and 
maintain glycemic goals long term. In this review, we briefly 
examine the pathophysiology of T2DM, with an emphasis 
on the role of the TZD pioglitazone, incretin analogs, and 
specifically the DPP-4 inhibitors, with a special emphasis on 
alogliptin and the combination of pioglitazone-alogliptin.
Abnormal glucose homeostasis  
in type 2 diabetes
Insulin resistance and beta cell failure represent the two cor-
nerstone pathophysiologic abnormalities in T2DM.7,15–19 Liver, 
muscle, and adipose tissue are resistant to the actions of insulin. 
Basal hepatic glucose production (HGP) is increased despite 
elevated fasting plasma insulin   concentrations,   indicating 
the presence of hepatic insulin resistance. The increase in 
basal HGP is the primary disturbance   responsible for the 
elevation in fasting plasma glucose (FPG)   concentration, 
and impaired suppression of HGP by insulin contributes to 
postprandial hyperglycemia. The ability of insulin to increase 
glucose uptake by peripheral tissues (primarily muscle) is 
markedly reduced and this peripheral insulin resistance plays 
a major role in postprandial hyperglycemia.7,15 Insulin binds 
to the insulin receptor, resulting in tyrosine phosphorylation 
both of the insulin receptor and insulin receptor substrate-1 
with subsequent activation of phosphoinositol 3 kinase and 
Akt (Figure 1). Activation of the insulin signaling pathway 
leads to increased glucose transport into the cell, enhanced 
glucose   phosphorylation (hexokinase II), and stimulation of 
glycogen synthesis (glycogen   synthase) and glucose oxidation 
(  pyruvate dehydrogenase).
The adipocyte is also resistant to insulin, and the   accelerated 
rate of lipolysis contributes to day-long elevation in the plasma 
free fatty acid (FFA) concentration.20 Elevated plasma FFA 
levels aggravate insulin resistance in both liver and muscle.21 
FFA metabolites, such as long-chain FACoAs, impair 
  insulin   signaling and inhibit glycogen synthesis and glucose 
  oxidation.22 In addition, FFAs increase HGP in the liver7,16,23 Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and impair insulin signaling.24 Muscle and hepatic insulin 
resistance, in combination with impaired insulin secretion, are 
responsible for postprandial hyperglycemia (Figure 2).
Prior to the development of T2DM, the insulin resistance 
in liver and muscle is compensated by enhanced insulin 
secretion.7 With time, however, pancreatic beta cell function 
declines (both because of reduced beta cell sensitivity to 
  glucose and decreased beta cell mass) and the plasma glucose 
concentration rises. Both “glucotoxicity”25 and “lipotoxicity”26 
contribute to the decline in beta cell function. Even small 
increases in the mean plasma glucose   concentration, if 
  present on a chronic basis, can impair insulin secretion by 
beta cells.27 Additionally, elevated plasma FFA concentra-
tions impair insulin secretion and promote beta cell failure.28 
Beta cell dysfunction can be identified during the OGTT long 
before the diagnosis of T2DM. At the time of diagnosis of 
IGT, about 50%–60% of beta cell function has already been 
lost, while individuals in the upper tertile of IGT (two-hour 
  postprandial glucose 180–199 mg/dL) have lost approximately 
70%–80% of their beta cell function.29 Thiazolidinediones,30–33 
exenatide,34,35 and possibly the DPP-4 inhibitors,36,37 can slow 
or prevent the decline in beta cell function.
In addition to impaired insulin secretion and moderate to 
severe insulin resistance, T2DM patients have elevated fasting 
plasma glucagon levels that fail to suppress normally after a 
mixed meal and may even rise paradoxically.38–40   Evidence for 
hepatic hypersensitivity to glucagon has also been   provided.41 
The elevated plasma glucagon levels stimulate HGP and con-
Figure 1 insulin signaling system in healthy normal glucose tolerant A) and T2DM B) subjects.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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tribute to fasting and postprandial   hyperglycemia. During 
hyperglycemia, the rate of gastric emptying is normally 
slowed, resulting in a better match between glucose appear-
ance and glucose disappearance from the circulation. In 
contrast, patients with newly diagnosed T2DM, despite 
hyperglycemia, often have an abnormally accelerated gastric 
emptying rate.42 In this review, we first explore the use of 
pioglitazone for the treatment of T2DM, and then examine 
therapies designed to augment plasma GLP-1 levels.
Pioglitazone
insulin sensitivity and metabolic effects
Pioglitazone is a potent insulin sensitizer, which binds to the 
peroxisome-proliferator activated receptor-gamma, resulting 
in enhanced muscle, liver, and adipose tissue sensitivity to 
  insulin, with a resultant decline in fasting and postprandial 
plasma glucose levels.43–45 Pioglitazone also augments beta 
cell   function46 (Figure 3), reduces inflammation,47 improves 
endothelial dysfunction,48,49 corrects diabetic dyslipidemia,50 
and improves the defect in insulin signaling in muscle, leading 
to impaired glucose transport/metabolism results in increased 
generation of nitric oxide (NO). NO is a potent vasodilator 
and antiatherogenic molecule,51,52 and deficiency of NO 
contributes to the markedly increased rate of atherogenesis 
in T2DM individuals. The compensatory increase in insulin 
secretion that occurs as the beta cell tries to   compensate for 
the insulin resistance leads to   hyperinsulinemia,   causing 
excessive stimulation of the mitogen-  activated protein (MAP) 
kinase pathway which retains normal   sensitivity to insulin 
in T2DM patients. Activation of MAP kinase   stimulates 
  multiple   intracellular pathways involved in inflammation and 
  augments vascular smooth muscle cell growth and prolifera-
tion, thereby promoting atherosclerosis.53 TZDs, including 
pioglitazone, improve insulin signaling and insulin sensitivity 
in muscle,43,44 augment NO generation, and simultaneously 
inhibit the MAP kinase pathway, thus reducing the risk of 
atherosclerosis in T2DM (Figure 4).
Hepatic glucose metabolism
In the liver, pioglitazone increases splanchnic glucose 
uptake, reduces HGP via inhibition of gluconeogenesis, 
and decreases hepatic fat content.54 Belfort et al22 studied 
Figure 2 The triumvirate: insulin resistance in liver and muscle with impaired insulin 
secretion represent the three core defects in T2DM. Reproduced with permission 
from DeFronzo RA. Lilly lecture. The triumvirate: Beta-cell, muscle, liver. A collusion 
responsible for NiDDM. Diabetes. 1998;37:667–687.16 Copyright © 1998 American 
Diabetes Association.
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Figure 3 effect of thiazolidinedione (TZD) treatment on beta cell function.  
Abbreviations: PiO, pioglitazone; ROSi, rosiglitazone; SU, sulfonylurea; iSR, insulin secretion rate; AUC, area under the curve.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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55 subjects with T2DM or IGT and biopsy-confirmed 
nonalcoholic steatohepatitis. Subjects were randomized to a 
hypocaloric diet ± pioglitazone 45 mg/day. After six months 
of pioglitazone treatment, muscle/hepatic insulin sensitivity 
improved, liver fat content (measured by magnetic resonance 
spectroscopy) decreased by 54%, and liver aminotransferase 
levels were normalized. Liver biopsy demonstrated histologic 
improvements in steatosis, inflammation, ballooning necro-
sis, and fibrosis. Pioglitazone also reduced inflammation, as 
manifested by reductions in C-reactive protein (CRP), tumor 
necrosis factor alpha, and transforming growth factor-beta, 
and increased plasma adiponectin levels.
Adipose tissue
Pioglitazone also exerts positive effects on adipose tissue 
metabolism. By improving adipocyte sensitivity to the anti-
lipolytic effects of insulin, pioglitazone reduces plasma FFA 
levels,54,55 leading to enhanced insulin sensitivity in muscle/
liver and improved insulin secretion.55–57 Pioglitazone also 
causes a redistribution of fat from highly metabolically active 
visceral fat (which is associated with accelerated atherogen-
esis) to subcutaneous fat stores (Figure 5).
Lipids
Pioglitazone also improves diabetic dyslipidemia, increasing 
high-density lipoprotein (HDL) cholesterol, reducing 
plasma triglycerides, and causing a shift from small dense 
low-density lipoprotein (LDL) to larger more buoyant LDL. 
Pioglitazone has a neutral effect on LDL cholesterol. In 
contrast, rosiglitazone increases both LDL and triglyceride 
levels.50,58 Goldberg et al compared the metabolic effects 
of pioglitazone and rosiglitazone in lipid-lowering agent-
naïve subjects over 24 weeks. Pioglitazone significantly 
increased HDL and lowered triglycerides compared with 
rosiglitazone.50 These differences in plasma lipids may, in 
part, explain the adverse cardiovascular signal that has been 
reported with rosiglitazone.59,60
Pioglitazone dose-response effect
Miyazaki et al examined the effect of placebo and 
pioglitazone 7.5, 15, 30, and 45 mg/day daily for 26 weeks 
in subjects poorly controlled on diet alone. Patients taking 
previous antidiabetic therapy underwent a 6–8 week washout 
period. Compared with placebo, HbA1c was significantly 
reduced in the 15 mg (−1.3%), 30 mg (−2.0%), and 45 mg 
(−3.0%) groups versus placebo (1.2%). During the OGTT, 
the insulinogenic index (change in the area under the plasma-
concentration time curve [∆AUC] insulin/∆AUC glucose) in 
the 30 mg/day and 45 mg/day groups increased significantly 
versus placebo. Insulin sensitivity, measured by the Matsuda 
index of whole-body insulin sensitivity, improved with all 
doses of pioglitazone, and was greatest at the 45 mg/day 
dose. The hepatic insulin sensitivity index (k/FPG × fasting 
plasma insulin) was also significantly improved.61
Figure 4 Pioglitazone positively affects the insulin signaling system resulting in improved glycemic control, generation of nitric oxide and decreased MAP kinase pathway 
activation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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In summary, pioglitazone improves insulin sensitivity in 
liver, muscle, and adipose tissue, resulting in improvements 
in glucose and lipid metabolism.
Beta cell effects and impaired  
glucose tolerance
TZDs, along with the GLP-1 analogs, are the only classes 
of drugs that have been shown to enhance and preserve 
beta cell function.30–33,62–64 It is not widely recognized that 
individuals with IGT are already maximally/near maximally 
insulin resistant and have lost as much as 70%–80% of their 
beta cell function. At baseline in the ACT NOW (Actos Now 
for Prevention of Diabetes) trial (see subsequent discussion) 
subjects with IGT had a 48% reduction in insulin sensitivity, 
as measured by the Matsuda index, and a 78% reduction in 
ability of pancreatic beta cells to respond to an oral glucose 
load versus normal glucose tolerant individuals.65 Similar 
observations have been reported in the VAGES (Veterans 
Administration Genetic Epidemiology Study) and SAM (San 
Antonio Metabolism) studies.29,66
Buchanan et al first reported on the use of troglitazone 
400 mg daily versus placebo in Hispanic women with a 
previous history of gestational diabetes and IGT. Over a 
30-month follow-up period, troglitazone reduced the risk 
of diabetes by 55%, and this protective effect persisted 
eight months after discontinuation of troglitazone   therapy.31 
Subjects who completed the study without diabetes were 
asked to continue in an open-label observational study 
using pioglitazone 45 mg daily for up to three years.32 The 
annual incidence of diabetes remained low (about 5%), 
similar to the rate observed during troglitazone treatment. 
The best predictor of reduced risk of progression to diabetes 
was a reduction in early insulin output, as measured by the 
frequently sampled intravenous glucose tolerance test. Sub-
jects who failed to reduce insulin output during TZD therapy 
did not have a significant reduction in the risk for T2DM. 
Thus, “off-loading” the pancreatic beta cells was the best 
predictor for preventing the progression of IGT to T2DM.
Most recently, pioglitazone has been evaluated in 
a randomized, double-blind, placebo-controlled trial in 
602   subjects confirmed by OGTT to have IGT. Over a mean 
follow-up of 2.6 years, the risk of progression of IGT to 
T2DM was reduced by 70% (P , 0.000001). Pioglitazone 
significantly improved both insulin sensitivity (measured by 
the Matsuda index and frequently sampled intravenous glucose 
tolerance test) and pancreatic beta cell function (measured by 
the insulin secretion/insulin resistance [disposition] index).33 
In a double-blind, placebo-controlled, four-month study 
carried out in poorly controlled, drug-naïve, and sulfonylurea-
treated T2DM patients, both pioglitazone and rosiglitazone 
significantly improved beta cell function (Figure 3).57 In 
eight of eight long-term (.1.5 years), double-blind, placebo-
controlled or active comparator studies, pioglitazone, as well 
as rosiglitazone, caused a durable reduction in HbA1c
64–73 
(Figure 6). Such a durable reduction in HbA1c can only be 
explained by preservation of beta cell function.17
Figure 5 effect of thiazolidinediones (TZDs) on body fat distribution.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Cardiovascular effects
Both pioglitazone and rosiglitazone improve endothelial 
dysfunction, decrease high-sensitivity CRP, reduce elevated 
levels of prothrombotic and inflammatory cytokines, 
increase plasma adiponectin, and reduce blood pressure.47,74 
Pioglitazone also lowers plasma triglycerides, raises HDL 
cholesterol, and converts small dense LDL particles to larger, 
more buoyant, less atherogenic particles. Both TZDs reduce 
restenosis after coronary stent placement, and decrease the 
need for revascularization when given up to six months after 
stent placement.75
Pioglitazone has also been associated with a reduced risk 
of cardiovascular disease. In a meta-analysis of pioglitazone 
studies, Lincoff et al76 reported that the combined endpoint of 
death, myocardial infarction (MI), and stroke was significantly 
reduced (hazards ratio [HR] 0.82, 95% confidence interval 
[CI] 0.72–0.94; P = 0.005]). The PROactive   (Prospective 
Pioglitazone Clinical Trial in Macrovascular Events) trial 
was designed to explore the cardiovascular   benefits of pio-
glitazone in T2DM subjects at high cardiovascular risk. Entry 
criteria included history of a prior cardiovascular event. In 
this double-blind,   randomized, placebo-controlled study, 
eligible subjects were assigned to pioglitazone 45 mg/day or 
placebo for three years. The primary endpoint (composite of 
death, MI, stroke, leg amputation, acute coronary syndrome, 
cardiac bypass, or leg revascularization) was reduced by 10% 
but this did not reach statistical significance because of an 
increase in leg revascularization (HR 0.90, 95% CI 0.80–1.02; 
P = 0.095). There were 195 events in the pioglitazone group 
versus 240 in the placebo group. The principal secondary 
endpoint   (Kaplan-Meier time to death, non-fatal MI, or stroke) 
was reduced by 16% and did reach statistical significance 
(HR 0.84, 95% CI 0.72–0.98; P = 0.027).77 In   conclusion, 
pioglitazone was effective in reducing cerebral and car-
diac events, but did not decrease peripheral arterial events. 
Interestingly, only subjects with baseline peripheral artery dis-
ease had an increased risk of leg revascularization (HR 1.68, 
95% CI 1.15–2.47; P = 0.008). Subjects without peripheral 
artery disease at baseline had no higher risk of leg revascu-
larization. Overall, pioglitazone tended to reduce the primary 
composite endpoint and significantly reduced the principal 
secondary endpoint of time to death, MI, and stroke.
In addition to the Lincoff meta-analysis76 and PROactive,77 
two ultrasound studies have provided evidence of anatomic 
regression of atherosclerotic disease. In the CHICAGO 
(Carotid Intima-Media Thickness in Atherosclerosis Using 
Pioglitazone) study, T2DM subjects were randomized 
to pioglitazone or glimepiride for 18 months and carotid 
intima-media thickness was measured before and after 
randomization. In pioglitazone-treated subjects, carotid 
intima-media thickness did not progress (−0.001 mm), 
whereas subjects receiving glimepiride had significant 
atherosclerosis progression (+0.012 mm). The absolute 
difference between treatment groups was −0.013mm (95% 
CI −0.024 to −0.002; P = 0.02).69
PERISCOPE (Pioglitazone Effect on Regression of 
Intravascular Sonographic Coronary Obstruction Prospective 
Evaluation) was a prospective, randomized, double-blind 
study comparing the effect of 18 months of pioglitazone 
versus glimepiride on coronary atheroma volume, quan-
titated with intravascular ultrasound. After 18 months 
pioglitazone reduced the percentage atheroma volume 
from baseline (−0.16%), whereas glimepiride significantly 
increased the percentage atheroma volume by 0.73% (95% 
CI 0.33%–1.12%; P , 0.001), resulting in a significant dif-
ference between treatment groups (P = 0.002).67
Side effects
Side effects encountered with all TZDs, including pioglitazone, 
include fat weight gain, fluid retention, and bone fractures. 
Paradoxically, the greater the fat weight gain, the greater is the 
decrease in HbA1c and the greater are the increases in insulin 
sensitivity and beta cell function.78,79 Thus, the fat weight 
gain is purely a cosmetic, not a metabolic, issue. Fluid reten-
tion occurs in 5%–10% of TZD-treated T2DM patients who 
are inadequately controlled with sulfonylureas, metformin, 
and/or insulin and less than 1% of these individuals develop 
congestive heart failure (CHF).80,81 In PROactive, diabetic 
subjects who developed CHF on pioglitazone had no increase 
in mortality,77 and in a study by Masoudi et al82 TZD-treated 
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diabetic individuals who developed CHF had a lower risk of 
mortality at one-year compared with individuals not treated 
with an insulin sensitizer. Because of occult diastolic dys-
function in T2DM subjects, fluid overload can lead to CHF. 
Therefore, pedal edema, an easily detected clinical sign for 
volume overload, should be treated promptly and aggressively 
with diuretics (triamterene, spironolactone, amiloride) 
that work in the collecting duct,83,84 and reduction in the 
pioglitazone dose if necessary to promote diuresis. If the pedal 
edema does not resolve, pioglitazone should be discontinued. 
This will minimize the risk of CHF. There is a small increase 
in the incidence (approximately one per 100 patient treatment 
years) of bone fractures in postmenopausal diabetic women 
treated with TZDs.5 An increased incidence of fractures has 
not been seen in premenopausal women or men. The fractures 
most commonly are related to trauma and involve the distal 
portions of the long bones of the extremities. To negate the 
fracture risk completely, one simply could avoid the use of 
TZDs in postmenopausal women. Alternatively, one could 
consider obtaining a bone mineralization scan and, if bone 
density is reduced, avoid the use of TZDs.
Pharmacoeconomic considerations may play a role in 
the use of pioglitazone in some managed markets, although 
the previous discussion should clearly delineate TZDs as a 
unique class of medication for the treatment of T2DM. The 
cost-effectiveness of pioglitazone, using the CORE (Center 
for Outcomes Research) diabetes simulation model on the 
PROactive study data and discounting 3.5% per annum, was 
examined. Pioglitazone, using a 35-year time horizon of use, 
was shown to provide an incremental cost-effectiveness ratio 
(cost per quality-adjusted life year gained) of ,$50,000 based 
on 2005 dollars, which is considered to be cost-effective.85
Summary
In summary, because of the beneficial effects of pioglitazone 
on insulin sensitivity, beta cell function, durable HbA1c 
control, and cardiovascular disease, in conjunction with a low 
risk of hypoglycemia and manageable side effects, we feel 
that pioglitazone should be considered as first-line therapy 
in T2DM patients.
Incretinomimetic agents
Glucose-dependent insulin secretion  
and loss of incretin effect
The incretin effect accounts for approximately 70% of all 
insulin that is secreted during an OGTT in normal glucose 
tolerant subjects,86 and GLP-1 and glucose-dependent 
insulinotrophic polypeptide (previously called gastric 
inhibitory polypeptide, GIP) account for over 90% of the 
incretin effect. GLP-1 is secreted from the L-cells in the distal 
small intestine/colon in response to mixed meals (glucose or 
fat). Circulating concentrations of GLP-1 rise rapidly within 
minutes after food ingestion indicating that neural signals, 
initiated by food entry in the proximal gastrointestinal tract, 
stimulate GLP-1 secretion via the L-cells.87 Acutely, GLP-1 
promotes normal glucose homeostasis by augmenting insulin 
secretion, inhibiting glucagon secretion and delaying gastric 
emptying.
GIP is secreted by the K-cells of the early small intestine 
in response to meal ingestion. However, unlike GLP-1, GIP 
does not inhibit glucagon secretion, does not slow gastric 
emptying, inhibit food intake, or promote weight loss.88 Both 
GLP-1 and GIP are rapid degraded by the DPP-4, which is 
ubiquitously present in plasma and on all cell membranes. 
Thus, the secreted GLP-1 and GIP have a short half-life in 
the range of 2–3 minutes.
As individuals progress from normal glucose tolerance to 
IGT to T2DM, stimulated GLP-1 levels decline89,90 (Figure 7), 
and there is beta cell resistance to the glucose-dependent 
stimulatory effect of both GLP-1 and GIP on insulin secre-
tion.91 In T2DM the contribution of incretin hormones to the 
insulin response has been estimated to be reduced to about 
36% in T2DM subjects.86,92 From the therapeutic standpoint, 
one can increase circulating GLP-1 levels by administering 
a GLP-1 analog that is resistant to DPP-4 degradation or by 
giving a DPP-4 inhibitor.7,93,94
The insulinotropic action of GLP-1 is glucose-dependent. 
In order for GLP-1 to enhance insulin secretion, the plasma 
glucose concentration must be higher than 90 mg/dL.95–99 In 
contrast, sulfonylureas stimulate insulin secretion irrespec-
tive of the ambient glucose concentration. Clinically, this 
results in an elevated risk of hypoglycemia with sulfony-
lureas. GLP-1 does not produce significant hypoglycemia. 
In addition to its stimulatory effect on insulin secretion, 
GLP-1 augments insulin biosynthesis and gene transcription, 
thereby restoring the cellular supplies of insulin for subse-
quent release.100–103 Of great interest, studies in animals have 
shown that GLP-1 stimulates islet neogenesis, causes beta 
cell replication, and inhibits beta cell apoptosis, leading to an 
increase in beta cell mass.104 However, short-term washout 
studies with exenatide suggest that exenatide is unlikely to 
increase beta cell mass in humans.64
elevated plasma glucagon levels
For over 30 years, it has been known that fasting plasma 
glucagon levels are increased in T2DM and that gluca-Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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gon secretion is not appropriately suppressed following 
a carbohydrate or mixed meal or may paradoxically 
increase.105–107 This abnormality is evident before the 
diagnosis of diabetes, and has been observed in subjects 
with IGT.108–110 Hyperglucagonemia in the fasting state 
results in excessive HGP and elevated FPG levels, while 
impaired suppression of plasma glucagon levels following 
a meal results in postprandial hyperglycemia. The main 
physiologic role of glucagon is to oppose the action of 
insulin on HGP in order to protect against hypoglycemia 
and restore normoglycemia.111 GLP-1 inhibits the inappro-
priately high glucagon secretion after a meal, both directly 
through the GLP-1 receptor on the alpha cell and indirectly 
by stimulating insulin secretion, although the absolute 
contribution of each component is still debated.112 This 
glucose-dependent inhibitory effect of GLP-1 on glucagon 
secretion reduces HGP and decreases postprandial plasma 
glucose levels.113
Correction of accelerated gastric 
emptying
The rate of gastric emptying is a key determinant of 
postprandial glucose excursion.114–116 Mismatch between 
the rate of glucose appearance in the systemic circulation 
and the rate of glucose disappearance can account for 
as much as 34% of the variability in peak postprandial 
glucose concentrations following glucose ingestion in 
normal glucose tolerant subjects.114,117,118 The normal 
physiologic response to hypoglycemia is to accelerate 
gastric emptying. This increases nutrient delivery into the 
systemic circulation and restores normal plasma glucose 
concentrations. During hyperglycemia, the rate of gastric 
emptying is slowed, resulting in a better match between 
glucose appearance and glucose disappearance from the 
circulation. Despite hyperglycemia, newly diagnosed 
T2DM patients often have an accelerated rate of gastric 
emptying that can exceed the rate of gastric emptying in NGT 
subjects by 25%–30%.116–119
GLP-1, which is deficient and to which the beta cell is 
resistant in T2DM, is a potent inhibitor of gastric emptying, 
and slows the rate of glucose appearance in the systemic 
circulation.86 GLP-1 agonists, such as exenatide, delay gastric 
emptying in healthy, nondiabetic subjects93 and in individuals 
with T2DM.113,120 The effect of GLP-1 and exenatide on 
inhibition of gastric emptying is centrally mediated by vagal 
afferent nerves.121
Reduction in food intake
GLP-1 administration reduces food intake and body weight 
in a dose-dependent manner. In animal models, the inhibitory 
effect on food intake is observed when GLP-1 is administered 
peripherally122 or intraventricularly.123,124 The inhibition of 
food intake by GLP-1 results from activation of GLP-1 recep-
tors in the hypothalamus and the area postrema, which are 
accessible from the systemic circulation.125 A meta-analysis 
of seven human studies has demonstrated that GLP-1 admin-
istration reduces energy intake and increases satiety in lean 
and overweight subjects.126
incretin formulations
Because the half-life of GLP-1 is extremely short (less than 
minutes), it is not practical for use in the treatment of T2DM 
patients. To overcome the rapid degradation of GLP-1 by 
DPP-4,127 two approaches have been developed, ie, alteration 
of the peptide structure of GLP-1 to prevent its degradation by 
DPP-4, but allow GLP-1 receptor activation, and development 
of DPP-4 inhibitors, which block the degradation of GLP-1 by 
DPP-4, thus increasing the reduced concentrations of GLP-1 
back to normal physiologic levels in T2DM.
In a mechanism of action study, DeFronzo et al10 compared 
sitagliptin, a DPP-4 inhibitor, with exenatide, a GLP-1 agonist. 
T2DM subjects on a stable dose of metformin were randomized 
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to sitagliptin 100 mg daily for two weeks or exenatide 5 µg 
bid for one week, then 10 µg bid for one week. Subjects were 
crossed over after two weeks and followed for an additional 
two weeks. At baseline and at the end of each two-week period, 
subjects received a meal tolerance test with acetaminophen to 
measure gastric emptying. After the initial two weeks of treat-
ment, the mean plasma glucose concentration and the two-hour 
post-meal plasma glucose concentration were markedly reduced 
in the exenatide versus sitagliptin groups (133 versus 208 mg/
dL, P , 0.001). The greater reduction in postprandial glucose 
excursion with exenatide was accounted for by a higher insu-
linogenic index, a greater inhibition of glucagon secretion, and 
delayed gastric emptying. Sitagliptin had no effect on gastric 
emptying, but did reduce plasma glucagon levels. The greater 
reduction in FPG and plasma glucagon concentrations and the 
greater increase in insulin secretion in the exenatide-treated 
group was explained by the pharmacologic exenatide levels 
achieved (64 pM) compared with the more physiologic GLP-1 
concentrations (15 pM) achieved with sitagliptin.10
Alogliptin
Alogliptin benzoate (formerly called SYR-322) is a non-
covalent, selective inhibitor of DPP-4.28 Active GLP-1 is 
rapidly converted to inactive GLP-1 (9-36 amide or 9-37 
amide) by the serine protease DPP-4. Alogliptin prevents 
the degradation of endogenous GLP-1 (and GIP), thus 
extending its half-life and restoring endogenous GLP-1 to 
normal physiologic levels.
Animal data
Rats with streptozotocin-induced diabetes and maintained on 
glibenclamide 10 mg/kg per day for 27 days were divided into 
four groups at 20 weeks of age and treated with placebo, gliben-
clamide 10 mg/kg/day, nateglinide 50 mg/kg/day, or alogliptin 
1 mg/kg/day prior to an oral glucose load (1 mg/kg). Alogliptin 
significantly increased the plasma insulin concentration at 
10 minutes and decreased the glucose AUC from 0–120 minute 
glucose compared with rats receiving glibenclamide and nat-
eglinide prior to the oral glucose load. In a separate group of 
diabetic rats, DPP-4 activity and plasma GLP-1 levels (GLP-1 
[7-36 amide] and GLP-1 [7-37 amide]) were inversely related 
to the dose of alogliptin over the range 0.03–3.0 mg/kg.129
Pertinent to the use of combined alogliptin-pioglitazone 
therapy, seven-week-old male Lepob/Lepob (ob/ob) mice 
and their nondiabetic male littermates received placebo, 
alogliptin 45.7 mg/kg/day, pioglitazone 4.0 mg/kg/day, or 
both (alogliptin-pioglitazone) for 33 days. In mice treated with 
alogliptin, plasma DPP-4 activity was inhibited by 80%, and 
plasma active GLP-1 levels were increased 3.5-fold and 4.1-
fold in the alogliptin alone and alogliptin-pioglitazone groups, 
without a change in the pioglitazone alone group. Insulin 
levels were increased approximately 1.5-fold in alogliptin- and 
pioglitazone-treated mice, and 3.2-fold in alogliptin-pioglitazone 
mice. Glucagon levels were decreased by approximately 25% 
in alogliptin-treated and alogliptin-pioglitazone treated mice, 
whereas no change was seen in the pioglitazone or placebo 
groups. Adiponectin increased only in mice who received 
pioglitazone. HbA1c levels decreased by 1.0, 1.5, and 2.3 in the 
alogliptin-, pioglitazone- and alogliptin-pioglitazone-treated 
mice, respectively. Pancreatic insulin content increased by 1.3-, 
1.5-, and 2.2-fold in mice treated with alogliptin, pioglitazone, 
and alogliptin-pioglitazone, respectively. In conclusion, the 
addition of alogliptin to pioglitazone produced completely addi-
tive metabolic and hormonal effects in ob/ob mice.130
Human data
Pharmacokinetic and pharmacodynamic profile
Healthy males (n = 36) received a single dose of alogliptin 
(five subjects for each dose at 25, 50, 100, 200, 400, or 
800 mg) or placebo (one subject per each dosing cohort) 
30 minutes prior breakfast, and pharmacokinetic and phar-
macodynamic parameters were measured over the next 24 
hours. Alogliptin was rapidly absorbed and reached maximal 
concentrations in approximately two hours. Over the dosing 
range, the rise in plasma alogliptin concentration was linear, 
and the t1/2 was approximately 16–20 hours after the single 
dose. In these normal healthy subjects, plasma GLP-1 levels 
increased 2.5- to 4.0-fold versus placebo over the 24-hour 
period, with the highest levels achieved 60–120 minutes after 
ingestion of the meal.131
In a second randomized, double-blind, placebo-controlled 
study, diet-treated T2DM subjects received alogliptin 25, 100, 
or 400 mg daily for 14 days. Alogliptin was rapidly absorbed, 
with a time to maximal concentration of about one hour. At 
14 days, the half-life was consistent at approximately 20 hours, 
supporting daily dosing of alogliptin. Most of the alogliptin 
(nearly 60%) was recovered unchanged in the urine after 
24 hours. The data suggest that alogliptin undergoes some renal 
secretion, and, similar to other marketed DPP-4 inhibitors, 
requires a dose reduction in patients with moderate to severe 
renal impairment.132,133 One active metabolite (N-demethylated 
alogliptin), which is as active as the parent compound, was 
identified, but it accounted for only 1% of the recovered drug. 
After 14 days, all three doses of alogliptin inhibited plasma 
DPP-4 by more than 80% at 24 hours.   Consistent with other 
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glucose levels, but plasma insulin   levels did not change 
significantly. However, the increment in   insulin per increment 
in glucose clearly increased, indicating an effect on the beta 
cells to augment insulin secretion. Glucagon levels were not 
measured but, in previously reported animal studies, plasma 
glucagon was reduced by 25%.128,134
Clinical studies
Alogliptin has been studied in T2DM subjects as   monotherapy 
and in combination with metformin, sulfonylureas,   pioglitazone, 
and insulin (see Figure 8). DeFronzo et al135 in a randomized, 
double-blind, placebo-controlled trial, reported on drug-naïve, 
poorly controlled (HbA1c 7.9% ± 0.8%) T2DM patients 
(n = 329) treated with alogliptin 12.5 and 25 mg/day or 
placebo for 26 weeks. Baseline   characteristics were similar 
(Table 1) in all three groups. Alogliptin 12.5 mg/day (−0.56% 
and −10 ± 4 mg/dL; P , 0.001 for both) and 25 mg/day 
(−0.59% and −16 ± 4 mg/dL; P , 0.001 for both) similarly 
reduced HbA1c and FPG compared with placebo (−0.02% 
and +11 ± 5 mg/dL). More subjects were able to achieve an 
HbA1c # 7.0% with alogliptin 12.5 mg/day (47.4%; P = 0.001) 
or 25 mg/day (44.3%; P = 0.008) versus placebo (23.4%). 
Approximately 50% of subjects on either dose of alogliptin had 
at least a $0.5% HbA1c reduction, and about 29% had a $ 1.0%   
reduction in HbA1c. Alogliptin was weight neutral and, at both 
doses, improved the proinsulin-to-insulin ratio. Alogliptin 
25 mg/day resulted in a small, but significant reduction in 
plasma total cholesterol and triglyceride concentration.
In a double-blind, randomized, placebo-controlled 26-week 
trial, Pratley et al136 compared alogliptin 12.5 and 25 mg/day 
versus placebo in 500 poorly controlled (mean HbA1c 8.1%) 
T2DM subjects taking background sulfonylurea therapy. 
Subjects were required to be on sulfonylurea monotherapy for 
at least three months prior to screening and had to be without 
serious concomitant diabetic complications. Subjects were 
switched to glyburide at equivalent dose, if necessary, and com-
pleted a four-week glyburide run-in period (Table 1). HbA1c was 
reduced in the alogliptin 12.5 mg/day (−0.39%) and 25 mg/day 
(−0.53%) groups versus placebo (+0.1%; both P , 0.001). As 
with other antihyperglycemic agents, the HbA1c reduction was 
correlated positively with baseline HbA1c. In subjects with a 
baseline HbA1c $ 9.0%, the HbA1c reduction with alogliptin 
12.5 mg/day (−0.82%) and 25 mg/day (−1.06%) were more 
robust. Weight increased slightly (0.6 kg) over the 26-week 
study, and there were no significant lipid changes.
In a randomized, double-blind, placebo-controlled 
trial of 26 weeks, Nauck et al137 treated poorly controlled 
T2DM with alogliptin 12.5 mg/day (n = 213), 25 mg/day 
(n = 210), or placebo (n = 104). Prior to randomization, all 
subjects entered a four-week run-in period on a stable dose 
of metformin $1500 mg/day (mean dose = 1847 mg/day). 
Subjects could not have significant diabetes-related complica-
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tions. At baseline, all three groups were well matched, with an 
HbA1c of 7.9%–8.0% and FPG of 168–180 mg/dL. HbA1c was 
significantly reduced by −0.6% on the 12.5 and 25 mg/day 
alogliptin doses versus placebo (−0.1%). The reduction from 
baseline in FPG was greater in the alogliptin 12.5 mg/day 
(−19 mg/dL) and 25 mg/day (−17 mg/dL) groups versus 
placebo (no change; both P , 0.001, Table 1).
Rosenstock et al138 explored the addition of alogliptin 
12.5 and 25 mg/day versus placebo in T2DM subjects 
inadequately controlled on insulin (at least 15 U/day but not 
more than 100 U/day) ± metformin therapy in a 26-week, 
randomized, double-blind, placebo-controlled trial. Sub-
jects were not allowed to have significant diabetes-related 
complications. The groups were well matched at baseline, 
with a mean HbA1c of 9.3%, FPG about 190 mg/dL, and 
diabetes duration of 12–13 years. At baseline all subjects 
were on insulin (64%, premix or insulin “combo”; 34%, 
long-acting insulin; 2%, short-acting insulin), and 60% 
of subjects were taking metformin (mean dose .1500 mg 
daily). After 26 weeks, alogliptin 12.5 and 25 mg/day signif-
icantly reduced HbA1c (−0.63% and −0.71%, respectively) 
compared with placebo (0.13%). Only alogliptin 25 mg/day 
significantly reduced FPG (−11 mg/dL; P = 0.03). Insulin 
doses were fairly stable throughout the 26-week study. 
Weight changes were similar in the placebo and alogliptin 
groups, and no significant changes in the lipid profile were 
noted (Table 1).
In all four of these trials,135–138 the reduction in HbA1c 
was 0.5–1.0% on mean (Figure 8). All four trials provided 
information on the number of subjects who required rescue 
therapy. For alogliptin in combination with metformin or 
glyburide, or as monotherapy, rescue therapy guidelines 
were FPG $ 275 mg/dL after more than one week of 
treatment, $ 250 mg/dL after week 4, and $225 mg/dL 
after week 8, or HbA1c $ 8.5% with a # 0.5% reduction 
from baseline by week 12.135–137 In the Rosenstock et al138 
paper, the rescue criteria were FPG $ 300 mg/dL after 
more than one week of treatment, $ 275 mg/dL after 
week 4, and $250 mg/dL after week 8, or HbA1c $ 8.7% 
with a # 0.5% reduction from baseline by week 12 (Figure 9). 
The combination of metformin with alogliptin required fewer 
hyperglycemic rescues, although no statistical analysis was 
done on the differences.
Adverse events and tolerability  
in Phase iii trials
DPP-4 inhibitors, including alogliptin, are very well 
tolerated.135–138 The incidence of all adverse events was, 
in general, similar to placebo, and not dose-dependent. 
Discontinuation rates were not different from placebo in any 
of the studies. The most common adverse events reported 
across studies were upper respiratory infection, urinary tract 
infection, nasopharyngitis, headache, diarrhea, arthralgia, and 
peripheral edema. Headache occurred more frequently than 
placebo in one study.135 Alogliptin monotherapy had slightly 
higher gastrointestinal events (abdominal pain, nausea, diar-
rhea, and vomiting) versus placebo. Other adverse effects of 
special interest were skin lesions and pruritus, which were 
closely monitored. Skin lesions were very rare. With alogliptin 
monotherapy, at 25 mg/day, one case of subcorneal pustular 
dermatosis was reported. There were no cases of skin lesions 
with glyburide-alogliptin.136 In the metformin-alogliptin study, 
skin lesions were observed in 7.7% of placebo versus 12% 
of alogliptin-treated subjects.137 In the insulin ± metformin 
study, skin lesions occurred in about 12% of alogliptin-treated 
patients versus 10.9% of patients receiving placebo.138 Pruritus 
occurred slightly more frequently with alogliptin. The sever-
ity of side effects was mild to moderate, and serious adverse 
events were not common and did not occur more frequently 
than placebo. Serious adverse events potentially related to 
alogliptin included one subject with cholecystitis and pan-
creatitis, one with CHF, one with pulmonary embolism, and 
one with severe hypoglycemia when alogliptin was combined 
with glyburide.135–138
Hypoglycemia rates were dependent upon concomitant 
therapy. In monotherapy, hypoglycemia rates were 1.5%–3.0% 
and similar to placebo.135 When alogliptin was combined with 
metformin, hypoglycemia occurred in 3% of the placebo 
group, 1% of the alogliptin 12.5 mg/day group, and in none of 
the subjects in the alogliptin 25 mg/day group.137 Hypoglyce-
mia was defined as ,60 mg/dL with symptoms or ,50 mg/dL 
50%
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Figure 9 Necessity for hyperglycemic rescue* in Phase iii trials with alogliptin.135-138
*see text for definitions 
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with or without symptoms. These clinical observations rein-
force the mechanism of action of endogenously-secreted 
GLP-1 on insulin secretion as being glucose-dependent and 
demonstrate that, when the DPP-4 inhibitor alogliptin is 
administered with agents that do not augment insulin secre-
tion, hypoglycemia is uncommon and does not occur more 
frequently than in the placebo group. Rates of hypoglycemia 
when alogliptin was combined with glyburide were 11.1% in the 
placebo group, 15.8% in the alogliptin 12.5 mg/day group, and 
9.6% in the alogliptin 25 mg/day group.136 When combined with 
insulin, 24%, 26.7%, and 27.1% experienced hypoglycemia in 
the placebo, alogliptin 12.5 mg/day, and alogliptin 25 mg/day 
groups, respectively.138 As expected, the rates of hypoglycemia 
were higher in insulin-treated T2DM patients, but alogliptin did 
not significantly exacerbate the risk of hypoglycemia.
Alogliptin selectivity
Selectivity of alogliptin for DPP-4 inhibition is defined as 
a . 10,000 greater affinity for the DPP-4 enzyme than for 
competing DPP enzymes, such as DPP-2, 8, and 9. Activation 
of DPP-8 and DPP-9 have been associated with untoward 
side effects, including thrombocytopenia, anemia, splenic 
enlargement, alopecia, and skin lesions. Therefore, selectivity 
for DPP-4 is desirable. DPP-4 inhibition can also prolong the 
action of endogenous peptides, such as pituitary adenylate 
cyclase-activating peptide, growth hormone-releasing hor-
mone, peptide YY, neuropeptide Y, and substance P, as well 
as several other chemokines. However, to date, alogliptin has 
not been reported to cause an increase in side effects that 
may be related to inhibition of the degradation of the above 
peptides, and short-term studies with doses of alogliptin up 
to 400 mg/day for 14 days in T2DM subjects have reported 
no dose-limiting toxicities.131
Drug–drug interactions
Alogliptin has not been associated with any significant drug-
drug or drug-food interactions. Alogliptin may be taken 
without regard to meals.139 Alogliptin has been studied in 
combination with pioglitazone, glyburide, metformin, cime-
tidine, cyclosporine, and digoxin. Pioglitazone increased the 
AUC of alogliptin by 10%, but this is considered to be of no 
clinical significance.140
Alogliptin–pioglitazone combination 
therapy
The combination of two antihyperglycemic agents with dif-
ferent, but complementary, mechanisms of action, a low risk 
of hypoglycemia, and easy, once-daily dosing is a logical 
step in the treatment of T2DM. Several studies or abstracts 
have examined this combination.
Pratley et al141 reported an international double-blind, 
randomized, placebo-controlled study in T2DM subjects 
randomized to alogliptin 12.5 mg/day (n = 197), alogliptin 
25 mg/day (n = 199), or placebo (n = 97). Subjects were on 
a TZD at baseline and, during a four-week run-in period, 
were stabilized on pioglitazone at 35 mg/day on average. 
If subjects were on pioglitazone, the current daily dose was 
continued; if on rosiglitazone, the subject was switched to 
the equivalent dose of pioglitazone, at 30 mg or 45 mg daily, 
and subjects were continued on metformin or sulfonylurea if 
their dose was stable for at least one month. At baseline, sub-
jects were well matched with respect to mean age (55 years), 
ethnicity (white, 74%), duration of diabetes (7.6 years), body 
mass index (BMI, 32.8 kg/m2), and baseline HbA1c (8.0%). 
Concomitant therapy was metformin in 55% (mean dose 
1688 mg/day), sulfonylurea in 20% (mean dose 37 mg/day), 
and no concomitant therapy (25%) at baseline. After 
26 weeks, HbA1c and FPG were significantly reduced from 
baseline versus placebo (alogliptin 12.5 mg/day: −20 mg/dL 
and −0.66%; alogliptin 25 mg/day: −0.8% and −20 mg/dL; 
placebo: −0.19% and −6 mg/dL). Subjects treated with either 
dose of alogliptin, 12.5 mg (44.2%) or 25 mg (49.2%), were 
more likely than placebo (34%) to reach the HbA1c goal 
of #7.0%, P = 0.01). The number of subjects achieving a 
HbA1c reduction $1.0% was two-fold greater in the alogliptin 
12.5 mg/day group and three-fold higher in the alogliptin 
25 mg/day group compared with placebo, and significantly 
fewer alogliptin subjects needed hyperglycemic rescue treat-
ment (Figure 9). Average weight gain was approximately 
1 kg with no significant differences between any of the 
three groups. Both doses of alogliptin were well tolerated 
and similar numbers of subjects (3%–4%) compared with 
placebo discontinued therapy due to adverse events. The 
total number of adverse events was similar (18%–19%) 
between alogliptin and placebo groups. Adverse reactions 
possibly related to alogliptin included one subject each with 
palpitations, CHF, road traffic accident, hypokalemia, serum 
sickness, and sudden death (no autopsy was performed). 
Hypoglycemia rates were dependent on baseline therapy. 
Importantly, in subjects taking the sulfonylurea–pioglitazone 
combination, rates of hypoglycemia were about 20% versus 
about 3% in subjects taking pioglitazone–metformin. This 
substantiates our previous observations that combination 
therapy with medications, such as metformin, pioglitazone, 
and GLP-1-based incretinomimetic agents, are associated 
with a very low risk of adverse effects and hypoglycemia. This Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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will increase the likelihood of patients continuing therapy 
and achieving glycemic goals.
Alogliptin–pioglitazone combination 
therapy
Combination therapy with alogliptin-pioglitazone has been 
examined in conjunction with various background therapies 
(Table 1). In a randomized, double-blind, placebo-controlled, 
26-week study, DeFronzo et al142 investigated the combination 
of alogliptin-pioglitazone in subjects inadequately controlled 
on metformin. Arms of the study included   placebo, aloglip-
tin 12.5 mg/day and 25 mg/day, pioglitazone 15 mg/day, 
30 mg/day, and 45 mg/day, and alogliptin 12.5 mg/day or 
25 mg/day combined with pioglitazone 15 mg/day, 30 mg/day, 
or 45 mg/day. For analysis, the authors pooled all doses 
of pioglitazone, alogliptin 12.5 mg/day plus any dose of 
pioglitazone, and alogliptin 25 mg/day plus any dose of 
pioglitazone. The mean change in HbA1c from baseline was 
−0.89% in the pioglitazone groups, −1.43% in the alogliptin 
12.5 mg + pioglitazone groups, and −1.42% in the alogliptin 
25 mg + pioglitazone groups (both alogliptin doses + pio-
glitazone were significant at P , 0.001 versus pioglitazone 
alone). The mean change in FPG was −28, −45, and −44 mg/
dL for the pioglitazone, alogliptin 12.5 mg + pioglitazone, 
and alogliptin 25 mg + pioglitazone groups, respectively.143 
The combination of alogliptin–pioglitazone significantly 
improved beta cell function measures of the proinsulin to 
insulin ratio and HOMA-IR versus pioglitazone alone (−0.087 
and 18.2; −0.076 and 22.2; −0.027 and 5.1, respectively). 
HOMA-IR improved in all groups, but did not reach statistical 
significance between groups (Table 1).143
In a randomized, double-blind, 26-week study, 655 
subjects (age 53 years, duration of diabetes 3.2 years, 
HbA1c 8.8%, FPG 191 mg/dL, BMI 21 kg/m2) inadequately 
controlled on diet and exercise were given an alogliptin–
pioglitazone combination (alogliptin 12.5 mg + pioglitazone 
30 mg or alogliptin 25 mg + pioglitazone 30 mg daily) or 
monotherapy with alogliptin 25 mg/day or pioglitazone 
30 mg/day. At 26 weeks, the decrements in HbA1c and FPG 
in the four groups were 1.7% and 50 mg/dL, 1.56% and 
48 mg/dL, 1.1% and 28 mg/dL, 0.96% and 26 mg/dL for the 
alogliptin 25 mg + pioglitazone 30 mg, alogliptin 12.5 mg + 
pioglitazone 30 mg, pioglitazone 30 mg/day, and alogliptin 
25 mg/day groups, respectively. HbA1c reduction was superior 
with both combination therapies compared with alogliptin 
alone (P , 0.001) and alogliptin 25 mg + pioglitazone 30 mg 
was superior to pioglitazone monotherapy (P , 0.001). 
Weight changes were +3.1, +2.5, +2.2, and −0.3.0 kg in 
the four groups, respectively. Hypoglycemia was #3.0% in 
all groups.144 Combination alogliptin-pioglitazone therapy 
improved beta cell function compared with alogliptin alone. 
Proinsulin to insulin ratio (30% versus 14%, P = 0.006), 
HOMA-β (67% versus 16%, P = 0.018), and HOMA-IR 
(46% versus 16%, P , 0.001) improved more in the aloglip-
tin 25 mg + pioglitazone 30 mg group than in the alogliptin 
25 mg/day alone groups. In addition, the increases in adi-
ponectin and decrease in high-sensitivity CRP were signifi-
cantly improved with alogliptin 25 mg + pioglitazone 30 mg 
versus alogliptin 25 mg/day monotherapy145 (Table 1).
Conclusion
Type 2 diabetes is characterized by at least eight pathophysi-
ologic abnormalities (Figure 10).17 The combination of 
alogliptin plus pioglitazone improves at least six of these 
pathophysiologic disturbances, including improved insulin 
resistance in skeletal muscle (→↑ muscle glucose uptake), 
liver (→↓ hepatic glucose production), and adipocytes 
(↓ lipolysis →↓ plasma FFA), increased incretin effect, 
enhanced insulin secretion, and decreased glucagon secre-
tion (Figure 10). Insulin resistance is an early manifestation 
in individuals with IGT and T2DM and increases beta cell 
stress, contributing to beta cell failure and the eventual 
development of overt T2DM. Insulin resistance can be 
improved with insulin-sensitizing drugs. Metformin is a 
weak peripheral (muscle) insulin sensitizer, but improves 
hepatic insulin sensitivity and reduces HGP. TZDs, such as 
pioglitazone, are potent insulin sensitizers in both peripheral 
tissues (muscle and adipocytes) and liver. Beta cell function 
is markedly impaired in T2DM, and alpha cell secretion of 
glucagon is increased. GLP-1 is deficient in T2DM, and 
beta cell responsiveness to GLP-1 is markedly impaired. On 
average, the incretin effect in T2DM individuals is reduced 
by approximately half compared with nondiabetic patients. 
GLP-1 increases insulin secretion, decreases glucagon, slows 
gastric emptying, and results in satiety and weight loss. The 
two methods of replacing GLP-1 include GLP-1 receptor 
agonists, which are effective in mimicking all the actions of 
GLP-1. Blocking the endogenous enzyme, DPP-4, which 
degrades active GLP-1, which is also effective in elevating 
to normal the reduced circulating GLP-1 levels that are pres-
ent in T2DM. DPP-4 inhibitors augment beta cell function 
and simultaneously reduce elevated plasma glucagon levels 
in T2DM patients.
Alogliptin has been studied as monotherapy and in 
combination with metformin, sulfonylureas, TZDs, and 
insulin. Alogliptin significantly improves HbA1c, is weight Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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neutral, does not cause hypoglycemia unless combined with 
an insulin secretagogue or insulin, has few associated side 
effects, and very few people discontinue the medication due 
to intolerance. Pruritic reactions appear to be slightly higher 
with alogliptin versus placebo, but no significant increase in 
skin lesions has been observed. The alogliptin–pioglitazone 
combination reverses multiple metabolic defects in T2DM 
(Figure 10). With regard to the beta cell defect, pioglitazone 
decreases lipotoxicity and exerts direct effects via the peroxi-
some-proliferator activated receptor-gamma to augment insulin 
secretion, while alogliptin improves islet function by increasing 
insulin secretion and lowering glucagon secretion in response 
to elevated plasma glucose levels. Alogliptin–pioglitazone 
gives an additive effect to improve HbA1c and reduce FPG, 
while the risk of hypoglycemia is similar to that with placebo. 
Alogliptin is weight neutral, whereas alogliptin–pioglitazone 
combination therapy is usually associated with a 1–3 kg of 
weight gain during the first year of treatment. Combination 
therapy also reduces high-sensitivity CRP and increases adi-
ponectin levels. CHICAGO, PERISCOPE, and PROActive 
demonstrate that pioglitazone has positive effects on vascular 
function and reduces cardiovascular events. The combination 
of pioglitazone–alogliptin addresses insulin resistance and islet 
cell dysfunction in T2DM patients in a once-daily medication 
that is well tolerated, effectively lowers HbA1c, and has a very 
low risk of hypoglycemia. In summary, alogliptin–pioglitazone 
combination therapy can reverse known several pathophysi-
ologic processes in T2DM and is clinically effective.
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